Intravenous Immunoglobulin in the Therapeutic Armamentarium of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

Rajalingham Sakthiswary, MRCP, and David D’Cruz, FRCP

Abstract: Prepared from the plasma of thousands of blood donors, therapeutic intravenous immunoglobulin (IVIg) mostly consists of human polyspecific immunoglobulin G (IgG). The use of IVIg in systemic lupus erythematosus (SLE) is still considered experimental without any clear indications.

The purpose of this systematic review is, therefore, to evaluate the available evidence to determine the therapeutic role of IVIg in SLE. A comprehensive, computerised search was performed in the MEDLINE (Pubmed), Scopus, EMBASE, and Cochrane controlled trials.

The study eligibility criteria were randomized controlled trials, and prospective and retrospective observational studies that examined the efficacy of IVIg in adult patients with SLE who were considered the participants.

IVIg therapy was the mode of intervention in these patients. Data abstracted included the study design, study population, changes in the disease activity scores (Systemic Lupus Erythematosus Disease Activity Index, Systemic Lupus Activity Measure, and Lupus Activity Index-Pregnancy), steroid dose, complement levels, autoantibodies, and renal function. Thereafter, data analysis established statistical procedures for meta-analysis.

Thirteen studies (including 3 controlled and 10 observational) were eligible for inclusion. There was significant reduction in the SLE disease activity scores with IVIg therapy with a standard mean difference of 0.584 (P = 0.002, 95% confidence interval [CI] 0.221–0.947). In terms of rise in complement levels, the response rate was 30.9% (P = 0.001, 95 CI 22.1–41.3). The effects of IVIg on other clinical outcome measures including anti-double-stranded DNA, antinuclear antibody, average steroid dose, and renal function could not be determined because of the limited numbers of trials.

The limitations of this review were lack of well-designed controlled trials with adequate sample size on the use of IVIg in SLE.

In conclusion, the use of IVIg is associated with significant reduction in SLE disease activity and improvement in complement levels.

Abbreviations: ANA = antinuclear antibody, antidsDNA = anti-double-stranded DNA, CI = confidence interval, ESR = erythrocyte sedimentation rate, IVIg = intravenous immunoglobulin, LAI-P = Lupus Activity Index-Pregnancy, SLAM = Systemic Lupus Activity Measure, SLE = systemic lupus erythematosus, SLEDAI = Systemic Lupus Erythematosus Disease Activity Index.

INTRODUCTION

Therapeutic preparations of intravenous immunoglobulin (IVIg) are derived from the plasma of healthy individuals by cold ethanol fractionation. The majority of commercial preparations of IVIg predominantly consist of polyclonal immunoglobulin G (IgG) (>90%). IgM, IgA, and traces of soluble molecules including human leukocyte antigen are also present in small quantities. IVIg, which was formulated in the 1960s, was initially used as a replacement therapy in immunodeficiency disorders. It was not until the 1980s that IVIg was tested in the treatment of systemic lupus erythematosus (SLE). Although the exact mechanism of action of IVIg as an immunomodulator remains unclear, it has been postulated that the Fc portion of the IgG is the key orchestrator in this regard. The Fc portion binds to the Fc receptors of the macrophages that, in turn, inhibits the binding of the autoantibody-coated targets to these receptors. Moreover, IVIg exerts its therapeutic properties by inhibiting the formation of membrane attack complex through the binding of the Fc portion to the complement components C3b and C4b.

To date, in SLE, there are only 4 drugs, namely, hydroxychloroquine, corticosteroids, belimumab, and aspirin, approved by the Food and Drug Administration (FDA). As such, the use of IVIg in SLE remains off-label and unlicensed. Many clinicians are unsure of the role of IVIg in SLE, especially in the present era of biologic therapies. Although IVIg may not be necessary in patients with mild SLE, who are well controlled with conventional immunosuppressants, most clinicians would consider IVIg as an option in patients who are either refractory to or have contraindications for standard therapies such as cyclophosphamide, mycophenolate mofetil, and azathioprine.

In the last few decades, several clinical studies, mostly uncontrolled, have examined the effects of IVIg in SLE, with variable results. Hence, the main objective of this systematic review is to summarize the results of these studies and evaluate the therapeutic role of IVIg in SLE.
METHODOLOGY
Search Strategy and Study Selection

The MEDLINE, EMBASE, SCOPUS, ISI Web of Science, and Cochrane controlled trials register were searched using the search terms “systemic lupus erythematosus,” “lupus,” and “SLE” (both as medical subject heading and free text). These were combined using the set operator “and” with studies identified with the terms “intravenous immunoglobulin” and “IVIg.” This search was completed by using standard Internet search engines. No date restrictions were applied in the selection process of the relevant articles. When faced with insufficient or incomplete data, authors of the respective studies were directly contacted through e-mail. All clinical studies including randomized controlled trials, and prospective and retrospective observational studies that examined the effects of IVIg in adult SLE patients were eligible for inclusion.

Other inclusion criteria included:
1. Diagnosis of SLE based on either American College of Rheumatology criteria or the treating physician’s opinion.
2. Treatment with intravenous immunoglobulin.
3. Administration of placebo or standard therapy for patients randomized to the control arm in case–control studies.

The Abstract of the studies identified by initial screening were scrutinized for appropriateness before retrieving the full text of the articles. The bibliographies of relevant studies were thoroughly checked to get additional references. Moreover, relevant unpublished trials, conference proceedings, and trial registries were identified from the references of these studies. Only articles that were published in English were considered. Ethical approval was not necessary for this meta-analysis as the results for publication onlyinvolved de-identified pooled data from individual studies that have received ethics approval. Figure 1 summarizes the algorithm followed for the selection of studies.

Data Extraction

The following data were extracted from all studies included in this systematic review: study design, study population, sample size, dose, and duration of IVIg therapy. The details of the control arm employed were recorded for all the controlled trials. Outcome measures that were studied included:

1. disease activity scores (Systemic Lupus Erythematosus Disease Activity Index [SLEDAI], Systemic Lupus Activity Measure [SLAM], and Lupus Activity Index-Pregnancy [LAI-P]),
2. steroid dose reduction,
3. change in the levels of autoantibodies (anti-double-stranded DNA [anti-dsDNA], antinuclear antibody [ANA], anti-SSA, and anti-SSB),
4. change in complement 3 (C3) and 4 (C4) levels,
5. renal function (proteinuria, creatinine).

Data Synthesis and Statistical Analysis

Data were pooled from controlled and uncontrolled studies using a random effects model for a more conservative estimate of the effects of IVIg therapy on disease activity scores and complement levels. This model allows for heterogeneity across the studies.6 The above outcome measures were expressed as standard difference in means or event rate with 95% confidence intervals. As there were only 2 studies with controls,7,8 the control groups were not included in the statistical analysis.

The remaining outcome variables (steroid dose, autoantibodies, renal function) were not statistically analyzed owing...
to the small numbers of studies and unavailability of data on mean values or response rate. Heterogeneity was statistically studied using the $I^2$ test, with values of $>50\%$ being deemed indicative of heterogeneity. Comprehensive meta-analysis software version 2.0 statistical programme was used for data analysis and generating the forest plots.

RESULTS

A total of 13 studies met the eligibility criteria and were included in this systematic review,8,10–20 (see Table 1). These included 1 randomized controlled trial,7 2 nonrandomized controlled trials,8,20 6 prospective observational studies,10–13,15,19 and 3 retrospective studies.16–18 Among the selected studies, only 3 had employed controls,7,8,21. The patients in the control arm were either on corticosteroids and nonsteroidal anti-inflammatory drugs or cyclophosphamide as the comparator drug.7

Majority of the studies (7/13) originated from Europe,7,11,12,15,18,21 followed by Asia (5/13)13,14,16,17,19 and the United States (1/13).10 Of note, all 4 studies from Asia were conducted in Israel. To date, there are no studies in this regard from Africa or Australia. These studies were all published between 1989 and 2013, and the duration of the individual studies ranged from 1 to 24 months. The sample sizes of the individual studies ranged from 7 to 132 subjects. The dose of IVIg per course of treatment used in most of the studies was 400 mg/kg/d over 5 days. Across the studies, the study populations were rather heterogeneous in terms of clinical manifestation of SLE. Five studies involved subjects with lupus nephritis,7,11,14,19,20 2 were on hematological,10,11 and 1 on cutaneous involvement15 in SLE. Most studies did not clearly state the specific numbers and reasons for dropouts.

Effect of IVIg on SLE Disease Activity

Six studies, with a total of 261 subjects, investigated the effect of IVIg on disease activity scores.8,12,13,16,17,20,21 The disease activity scores used as outcome measures included SLEDAI,16,17 SLAM,12,13 and LAI-P.8 The disease activity scores significantly decreased in all of the studies. An appreciable decline in the scores was seen as early as 6 weeks following the IVIg therapy.12

Figure 2 shows the forest plot of the aforementioned studies. The pooled analysis of these studies suggests that IVIg is associated with significant reduction in disease activity scores on random effects model with a standard mean difference of 0.584 ($P = 0.002$, 95% confidence interval [CI] 0.221–0.947). The inter-study heterogeneity test yielded a statistical significance of $P = 0.003$, with $I^2$ of 78.42%.

IVIg as a Steroid-Sparing Agent

Three studies, with a total of 45 subjects, investigated the effect of IVIg as a steroid-sparing agent.5,13,17 Levy et al13 and Zandman-Goddard et al17 reported a significant reduction in the average daily dose of corticosteroids. The pooled data from the above studies demonstrated a mean reduction of 17.95 mg/d in the dose of corticosteroids with IVIg therapy. Boletis et al7 compared the cumulative steroid dose between the IVIg and the cyclophosphamide-treated patients. The cyclophosphamide arm tended to have a higher dose (4719 vs 3334 mg), but this difference, however, did not reach statistical significance.

Effect of IVIg on Complement Levels

Eight studies investigated the changes in complement levels.5,10–13,16,19,21 The results were rather conflicting. Francioni et al,11 Perricone et al,8 and Sherer et al6 reported a rising trend in complement levels with IVIg therapy whereas Maier et al,10 Monova et al,20 and Schroeder et al12 demonstrated no changes in this parameter. Levy et al13 surprisingly found a significant decline in C4 levels with the above treatment ($P = 0.007$).

The changes in the complement levels were reported as number of responders (subjects with increment in complement levels)/total number of subjects on IVIg therapy in 6/8,10–12,16,19 of the studies with a total of 114 patients. The results showed a pooled response rate of 30.9% ($P = 0.001$, 95% CI 22.1–41.3), using the random effects model. The heterogeneity test yielded a value of $I^2 = 72.66\%$ that was statistically significant ($P = 0.006$) (Figure 3).

Effect of IVIg on Autoantibodies

Four studies investigated the changes in the quantitative values of ANA and antidsDNA with IVIg therapy.8,12,13,20 Two out of 4 of the studies demonstrated no significant changes in the levels of ANA. AntidsDNA, on the other hand, showed significant reduction in 3/4 studies.8,12,20 Two of the studies looked into the serial levels of anti-SSA and anti-SSB.

| Study name     | Std Diff in Means | Standard error | Lower Limit | Upper Limit | $P$ Value | Std diff in means and 95% CI |
|---------------|-------------------|----------------|-------------|-------------|-----------|--------------------------------|
| Sherrer et al. | 0.435             | 0.133          | 0.175       | 0.696       | 0.001     | 0.375 0.221 0.947 0.002 Favors IVIg |
| Schroeder et al.| 0.447             | 0.303          | −0.146      | 1.040       | 0.140     | 0.375 0.221 0.947 0.002 Favors IVIg |
| Levy et al.   | 1.901             | 0.375          | 1.166       | 2.635       | 0.000     | 0.375 0.221 0.947 0.002 Favors IVIg |
| Perricone et al.| 0.502             | 0.217          | 0.077       | 0.926       | 0.021     | 0.375 0.221 0.947 0.002 Favors IVIg |
| Monova et al. | 0.215             | 0.088          | 0.042       | 0.387       | 0.015     | 0.375 0.221 0.947 0.002 Favors IVIg |
| Effect size   | 0.584             | 0.185          | 0.221       | 0.947       | 0.002     | 0.375 0.221 0.947 0.002 Favors IVIg |

Meta-analysis

FIGURE 2. Meta-analysis of the effect of IVIg on disease activity scores. CI = confidence interval, IVIg = intravenous immunoglobulin.
| Ref | Country     | Study Design                  | Study Population                                                                 | Outcome Measures | Findings                                                                 |
|-----|-------------|-------------------------------|----------------------------------------------------------------------------------|------------------|--------------------------------------------------------------------------|
| Lin CY, 1989 | Taiwan | Prospective, observational      | 9 patients with lupus nephritis who did not respond to steroids and cyclophosphamide | Proteinuria       | Decreased in 3 patients with Class IV lupus nephritis.                   |
|      |            |                               |                                                                                  | Creatinine       | Decreased in 3 patients with Class IV lupus nephritis.                   |
|      |            |                               |                                                                                  | C3 and C4        | Increased in 3 patients with Class IV lupus nephritis.                   |
|      |            |                               |                                                                                  | Platelet count   | 5/7 patients had >50% increase in their platelet counts by day 28.       |
|      |            |                               |                                                                                  | C3 and C4        | No changes (remained low).                                              |
|      |            |                               |                                                                                  | Hemoglobin       | Levels increased in 11/12 patients.                                      |
| Maier et al, 1990 | United States | Prospective observational study for 28 d | 7 SLE patients with thrombocytopenia                                              | C3, C4           | Levels increased in 11/12 patients.                                      |
|      |            |                               |                                                                                  | Platelet count   | 2/2 patients showed an increase.                                        |
|      |            |                               |                                                                                  | ESR              | Progressive reduction in 11/12 patients.                                 |
|      |            |                               |                                                                                  | Urea             | Marked improvement in all renal patients.                               |
|      |            |                               |                                                                                  | C3, C4 clearance | Marked improvement in all renal patients.                               |
| Francioni et al, 1994 | Italy | Prospective observational study for 24 mo | 12 SLE patients refractory to conventional treatments                            | C3, C4           | Marked improvement in all renal patients.                               |
|      |            |                               |                                                                                  | Platelet count   | No changes (remained low).                                              |
|      |            |                               |                                                                                  | ESR              | Progressive reduction in 11/12 patients.                                 |
|      |            |                               |                                                                                  | Urea             | Marked improvement in all renal patients.                               |
|      |            |                               |                                                                                  | C3, C4 clearance | Marked improvement in all renal patients.                               |
| Schroeder et al, 1996 | Germany | Prospective observational study for 6 wk | 12 SLE patients with mildly to moderately active disease                          | SLAM             | Declined from 7.33 (range 3–15) to 5.25 (range 0–10) ($P < 0.01$).       |
|      |            |                               |                                                                                  | Antid/sDNA       | Most patients showed a decline.                                         |
|      |            |                               |                                                                                  | ANA              | No significant changes.                                                  |
|      |            |                               |                                                                                  | C3, C4           | No significant changes.                                                  |
|      |            |                               |                                                                                  | SLAM             | Decreased from 19.3 ± 4.7 to 4 ± 2.9 ($P < 0.0001$)                      |
| Levy et al, 1999 | Israel | Prospective observational study for 1–8 mo | 20 SLE patients                                                                | Steroid dose     | Decreased from 29.7 ± 18.2 to 13.8 ± 16.7 mg/d ($P = 0.02$)             |
|      |            |                               |                                                                                  | ANA              | No significant changes.                                                  |
|      |            |                               |                                                                                  | dsDNAA           | No significant changes.                                                  |
|      |            |                               |                                                                                  | Anti-SSA or anti-SSB | Significant reduction ($P = 0.04$).                                      |
|      |            |                               |                                                                                  | ENA              | No significant changes.                                                  |
|      |            |                               |                                                                                  | C3, C4           | Significant reduction in C4 levels only ($P = 0.007$).                   |
|      |            |                               |                                                                                  | Creatinin clearance | No substantial changes (mean change of −8 μmol/L in both groups, $P = 0.83$). |
| Boletis et al, 1999 | England | Randomized controlled trial | 14 patients with proliferative lupus nephritis who had received cyclophosphamide 1 g/m² once a month for 6 mo with daily prednisone 0.5 mg/kg | Creatinine clearance | No significant difference between the 2 groups (mean change of 4 mL/min in IVIg group vs 8 mL/min in cyclophosphamide group, $P = 0.80$). |
| Study                       | Country      | Study Design                      | Treatment                        | Outcomes                                |
|-----------------------------|--------------|-----------------------------------|----------------------------------|-----------------------------------------|
| Levy et al, 2000            | Israel       | Pooled analysis of 7 cases        | IVIg for 2–6 mo                   | Proteinuria: Mean change was similar in the two groups (0.23 g/d vs 0.40 g/d, \( P = 0.71 \)). Cumulative prednisolone dose: Patients in the cyclophosphamide group used marginally more prednisone than those in the IVIg group (mean cumulative dose 4719 vs 3334 mg, \( P = 0.25 \)). |
| Goodfield et al, 2004       | United Kingdom | Prospective observational study for 6 mo | IVIg                         | Proteinuria: Plasma levels increased insignificantly from 26±8 g/L to 32±8 g/L. |
| Monova et al, 2006          | Bulgaria     | Nonrandomized controlled trial    | IVIg                             | SLEDAI: Decreased from 29.2 (15–64) to 4.2 (0–8) in the IVIg group. No changes. |

### Summary
- **IVIg** was effective in treating lupus nephritis, with patients showing significant decreases in proteinuria and cholesterol levels.
- The study by Goodfield et al. showed improved skin disease extent in some patients.
- Monova et al. reported decreases in SLEDAI, C3, and proteinuria with IVIg treatment.

(Continued)
| Study | Country | Study Design | Number of SLE Patients | Intervention | Outcome Measures | Results |
|-------|---------|--------------|------------------------|-------------|------------------|---------|
| Perricone et al, 2008 | Italy | Nonrandomized controlled study | 24 SLE pregnant patients with recurrent spontaneous abortions | LAI-P scale | Decreased from 0.72 ± 0.43 at the beginning of pregnancy to 0.13 ± 0.19 at the end of pregnancy (P < 0.0001) in the IVIg-treated group whereas the controls showed no significant changes. Antibodies and complement levels tended to normalize in the following number (%) of IVIg-treated patients versus controls: | |
| Sherer et al, 2008 | Israel | Retrospective | 62 SLE patients | SLEDAI | Significant and continuous decline in the scores from 15 ± 7.8 to 5.2 ± 5.7. | |
| Zandman-Goddard et al, 2012 | Israel | Retrospective | 11 SLE patients | C3 and C4 | Normalized in 27% of the patients. | |
| Camara et al, 2013 | United Kingdom | Retrospective | 53 SLE patients | Steroid dose | Significant reduction in the steroid dose by 20 mg/d (P < 0.05). | |

**Notes:**
- AntidsDNA = anti-double-stranded DNA
- IVIg = intravenous immunoglobulin
- LAI-P = Lupus Activity Index-Pregnancy
- NSAIDs = nonsteroidal anti-inflammatory drugs
- SLE = systemic lupus erythematosus
- SLEDAI = Systemic Lupus Erythematosus Disease Activity Index
anti-SSB autoantibodies.²⁻¹³ Levy et al.¹³ found significant reduction in these autoantibodies (P = 0.04) but Perricone et al.¹² had contradictory findings. In the latter study, the controls performed better (66.7% vs 33.3%) with regard to decline in the anti-SSA levels whereas for anti-SSB, both the treatment arms had a response rate of 100%. Pooled analysis of the autoantibodies was not performed as 2/4 studies¹²,¹³ did not provide data on the response rate.

**IVIg in Lupus Nephritis**

Only 5 of the selected studies in this review included patients with lupus nephritis.⁷⁻¹¹,¹⁴,¹⁹,²⁰ These studies evaluated the renal response to IVIg therapy with the following outcome measures: creatinine clearance,⁷,¹¹ creatinine,⁷,¹⁴ and proteinuria.⁷,¹¹,¹⁴ All studies consistently reported a decline in proteinuria with IVIg treatment. Boletis et al.⁷ and Monova et al.⁹ found that the improvement in proteinuria was comparable between the IVIg and the cyclophosphamide-treated group. There were no substantial changes in the creatinine in 2/5 of the studies,⁷,¹¹,¹⁴ although Francioni et al.¹¹ demonstrated marked improvement in creatinine clearance in all 12 subjects of the study. A pooled analysis of renal outcome measures was not possible owing to the absence of details on mean values in majority (3/5) of the studies.⁷,¹¹

**DISCUSSION**

This systematic review was designed to evaluate the effects of IVIg therapy in SLE. The highest strength of evidence for the cause-effect relation between treatment and outcome is derived from randomized controlled trials, but disappointingly, there is a paucity of such studies in this respect. Hence, data from uncontrolled observational studies were included in the statistical analysis as larger numbers of subjects may provide more accurate and valuable insights into the treatment effects of IVIg in SLE.

The results of this review highlights that IVIg therapy is associated with significant improvement in disease activity scores and complement levels. The vast majority (4/5) of the studies that examined the effects of IVIg on disease activity were observational. Observational studies have the tendency to overestimate treatment effects. However, across the studies there was remarkable consistency in the trend of the SLE disease activity scores, regardless of the study design.

The rationale behind employing IVIg in SLE relies on its promising results in other autoimmune diseases such as Kawasaki disease, immune thrombocytopenic purpura, autoimmune cytopenias, and antiRo/La-related congenital atrioventricular block.¹¹,²² IVIg interferes with the disease activity of SLE through complex processes that include various arms of the immune system, that is, Fc receptor blockade, complement regulation, and T-cell suppression.²⁵ IVIg preparations target cytokines including interferon γ, tumor necrosis factor α, and B-cell activating factor/APRIL (a proliferation-inducing ligand).²⁴ Besides, tregitopes (T-regulator cell epitopes) contained in the regions of the Fab and Fc of the IVIg induce expansion of CD4⁺/CD25 and FoxP3⁺ T cells.²⁵ As opposed to conventional immunosuppressants that predispose to systemic infections, IVIg offers the advantage of preventing infections and confers a passive immunity.²⁶,²⁷

The pooled analysis of the selected studies revealed a significant favorable response to IVIg therapy in terms of complement levels despite the inconsistencies throughout the studies. The discrepancies in the changes of the aforementioned parameter across the studies could be because of the diverse study populations, and methodological variations and the power of many of the studies was probably too low to achieve statistical significance. In clinical practice, complement levels are surrogate markers of SLE disease activity.²⁸,²⁹ In vitro C3 uptake studies suggest that IVIg produces a kinetic suppression of C3 uptake and modifies the process of complement fragment deposition on erythrocytes.³⁰

Based on the evidence from the small number of studies included in this review, IVIg appears to lower antidsDNA levels, the daily steroid dose requirement, and the severity of proteinuria. Although there is no robust data to support these findings, taken together these preliminary results imply that IVIg has a beneficial role as a steroid-sparing agent and maybe an alternative option in lupus nephritis. Krause et al.³¹ using experimental murine models of SLE, found that IVIg had anti-idiotypic activity both to anti-DNA and anti-cardiolipin antibodies. IVIg infusion did not only succeed in abrogation of experimental SLE and antiphospholipid syndrome but also restored the respective antibodies to normal levels.

**FIGURE 3.** Meta-analysis of the effect of IVIg on complement levels: response rates. CI = confidence interval, IVIg = intravenous immunoglobulin.

| Study name       | Effect size | Event Rate | Lower Limit | Upper Limit | Z Value | P Value | Event rate and 95% CI |
|------------------|-------------|------------|-------------|-------------|---------|---------|----------------------|
| Francioni et al. | 0.309       | 0.211      | 0.413       | –3.475      | 0.001   |         | –1.00 –0.50 0.00 0.50 1.00 |
| Perricone et al. | 0.333       | 0.111      | 0.667       | –0.980      | 0.327   |         | Favors IVIg          |
| Sherer et al.    | 0.063       | 0.004      | 0.539       | –1.854      | 0.064   |         |                     |
| Maier et al.     | 0.038       | 0.002      | 0.403       | –2.232      | 0.026   |         |                     |
| Schroeder et al. | 0.040       | 0.158      | 0.703       | –0.628      | 0.530   |         |                     |
| Lin et al.       | 0.063       | 0.178      | 0.398       | –3.419      | 0.001   |         |                     |
levels. Moreover, the anti-idiotypic antibodies of the IVIg preparations have inhibitory effects on the spontaneous secretion of antisDNA from blood mononuclear cells, as was demonstrated in vitro by Evans et al. \(^{32}\)

FDA data shows that out of 106 patients with lupus nephritis who were treated with IVIg, a sizable proportion showed improvement in proteinuria, nephrotic syndrome, and creatinine clearance.\(^{33}\) The Fc receptors (FcRRI [activating receptor for monomeric IgG], FcRRII [inhibitory immune complex receptor], and FcRIV [activating immune complex receptors]) have been postulated to contribute to the accumulation of IgG in the kidneys in SLE. IVIg could potentially alter the balance between the inhibitory and activating Fc receptors in the kidney resulting in more degradation and urinary excretion of pathogenic autoantibodies to minimize renal parenchymal injury.\(^{34}\) However, IVIg and the kidney receptors can be regarded as a 2-edged sword, since nephrotoxicity because of renal tubular necrosis can be a serious complication of IVIg therapy.\(^{35}\)

A Centers for Disease Control and Prevention report cited 120 cases of nephrotoxicity worldwide with this form of therapy.\(^{35}\)

There has been a paucity of well-designed controlled trials with adequate sample size on the use of IVIg in SLE. Although some of these studies reported statistically significant results, this may not necessarily be clinically meaningful. Besides, many of the studies in this review had a before–after design with limited ability to show causality. In uncontrolled studies, it is impossible to distinguish the possible effect generated by the intervention from the placebo effect or change resulting from the natural course of the disease.\(^{36}\)

In conclusion, the results of this systematic review seem to suggest that IVIg is effective in reducing SLE disease activity and increasing circulating complement levels. Owing to the profound lack of studies in the area of research, it is premature and would be fallacious to make any definitive claims for or against the role of IVIg in other clinical aspects. Further research to improve the therapeutic application of IVIg in SLE is much needed and probably relies on the conception of newer generation of immunoglobulin formulations.

**ACKNOWLEDGMENT**

_The author would like to thank the librarians of the Universiti Kebangsaan Malaysia, Cheras, Malaysia, for their assistance in retrieving the full text of the articles._

**REFERENCES**

1. Pyne D, Ehrenstein M, Morris V. The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. *Rheumatology (Oxford)*. 2002;41:367–374.
2. Koblet H, Barandun S, Diggelmann H. Turnover of standard-gammaglobulin, pH4-gammaglobulin and pepsin desaggregated gammaglobulin and clinical implications. * Vox Sang*. 1967;13:93–102.
3. Corvetta A, Della Bitta R, Gabrielli A, et al. Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. *Clin Exp Rheumatol*. 1989;7:295–299.
4. Okano M, Moriya K, Itadani Y, et al. Trial of IgG therapy for lupus nephritis-report of two cases with a successful response. *Nihon Jinzo Gakkai Shi*. 1989;31:145–149.
5. Basta M. Modulation of complement-mediated immune damage by intravenous immune globulin. *Clin Exp Immunol*. 1996;104:21–25.
6. DeSimionian R, Laird N. Meta-analysis in clinical trials. *Controlled clinical trials*. 1986;7:177–188.
7. Boletis JN, Ioannidis JP, Boki KA, et al. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. *Lancet*. 1999;354:569–570.
8. Perricone R, De Carolis C, Kroeber B, et al. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. *Rheumatology (Oxford)*. 2008;47:646–651.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327:557–560.
10. Maier WP, Gordon DS, Howard RF, et al. Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. *Arthritis Rheum*. 1990;33:1233–1239.
11. Francioni C, Galeazzi M, Fioravanti A, et al. Long-term i. v. Ig treatment in systemic lupus erythematosus. *Clin Exp Rheumatol*. 1994;12:163–168.
12. Schroeder JO, Zeuner RA, Euler HH, Loffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. *J Rheumatol*. 1996;23:71–75.
13. Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin: clinical and serologic response. *Lupus*. 1999;8:705–712.
14. Levy Y, Sherer Y, George J, et al. Intravenous immunoglobulin treatment of lupus nephritis. *Semin Arthritis Rheum*. 2000;29:321–327.
15. Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IV Ig) for therapy-resistant cutaneous lupus erythematosus (LE). *J Dermatol Treat*. 2004;15:46–50.
16. Sherer Y, Kuechler S, Jose Scali J, et al. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. *Isr Med Assoc J*. 2008;10:55–57.
17. Zandmann-Goddard G, Krauthammer A, Levy Y, et al. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune immune deficiency syndrome. *Clin Rev Allergy Immunol*. 2012;42:247–255.
18. Camara I, Sciascia S, Simoes J, et al. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre. *Clin Exp Rheumatol*. 2014;32:41–47.
19. Lin CY, Hsu HC, Chiang H. Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. *Nephron*. 1989;53:303–310.
20. Monova D, Monov S. Treatment of Active Lupus Nephritis: Intravenous Immunoglobulin G Versus Cyclophosphamide or Azathioprine. *BANTAO J*. 2006;4:13.
21. Monova D, Monov S. Intravenous Immunoglobulin G versus cyclophosphamide or azathioprine in the treatment of patients with lupus glomerulonephritis. *Nephrol Dial Transpl*. 2007;22:284.
22. Ruffatti A, Marson P, Svaluto-Moraglio G, et al. A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atriocentral block. A case series and review of the literature. *Autoimmun Rev*. 2013;12:768–773.
23. Ballow M. Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. *Cancer*. 1991;68(suppl 6):1430–1436.
24. Kaveti SV. Intravenous immunoglobulin: exploiting the potential of natural antibodies. *Autoimmun Rev*. 2012;11:792–794.
25. Coussens LP, Tassone R, Mazer BD, et al. Tregitope update: mechanism of action parallels IVlg. *Autoimmun Rev*. 2013;12:436–443.
26. Molica S, Musto P, Chiarazzi F, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. *Haematologica*. 1996;81:121–126.
27. Ferrara G, Zumla A, Maeurer M. Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections. *Am J Med*. 2012;125:e1–e8.

28. Ho A, Barr SG, Magder LS, et al. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. *Arthritis Rheum*. 2001;44:2350–2357.

29. Valentijn RM, van Overhagen H, Hazevoet HM, et al. The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. *Arthritis Rheum*. 1985;28:904–913.

30. Basta M, Langlois PF, Marques M, et al. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. *Blood*. 1989;74:326–333.

31. Krause I, Blank M, Kopolovic J, et al. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. *J Rheumatol*. 1995;22:1068–1074.

32. Evans M, Abdou NI. In vitro modulation of anti-DNA secreting peripheral blood mononuclear cells of lupus patients by anti-idiotypic antibody of pooled human intravenous immune globulin. *Lupus*. 1993;2:371–375.

33. Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney: a two-edged sword. *Semin Arthritis Rheum*. 2004;34:593–601.

34. Wenderfer SE, Thacker T. Intravenous immunoglobulin in the management of lupus nephritis. *Autoimmune Dis*. 2012;2012:589359.

35. Renal insufficiency and failure associated with immune globulin intravenous therapy—United States, 1985–1998. *MMWR Morbidity and mortality weekly report*. 1999;48:518–521.

36. Harris AD, Bradham DD, Baumgarten M, et al. The use and interpretation of quasi-experimental studies in infectious diseases. *Clin Infect Dis*. 2004;38:1586–1591.